Pharmacotherapy for Nonalcoholic Fatty Liver Disease

Seminars in Liver Disease

Volumn 35, Issue 3, 2015, Pages 338-348

  Gawrieh, Samer ^a   Chalasani, Naga ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; obeticholic acid; thiazolidinedione; Vitamin E

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; CENICRIVIROC; DIGESTIVE TRACT AGENT; ELAFIBRANOR; EXENDIN 4; FIBRIC ACID DERIVATIVE; FIBROBLAST GROWTH FACTOR 21; GR MD 02; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIRAGLUTIDE; MERCAPTAMINE; METFORMIN; OBETICHOLIC ACID; PENTOXIFYLLINE; PIOGLITAZONE; POLYUNSATURATED FATTY ACID; RESISTIN; ROSIGLITAZONE; SIMTUZUMAB; TELMISARTAN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VALSARTAN; VERY LOW DENSITY LIPOPROTEIN; GASTROINTESTINAL AGENT; NEW DRUG;

ARTICLE; DRUG EFFICACY; DYSLIPIDEMIA; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; LIVER FIBROSIS; LIVER HISTOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; WEIGHT GAIN; ANIMAL; DRUG EFFECTS; LIVER; METABOLISM; MOLECULARLY TARGETED THERAPY; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; DRUGS, INVESTIGATIONAL; GASTROINTESTINAL AGENTS; HUMANS; LIVER; MOLECULAR TARGETED THERAPY; NON-ALCOHOLIC FATTY LIVER DISEASE; TREATMENT OUTCOME;

EID: 84941911821     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0035-1562951     Document Type: Article

References (140)

1. Wong R. J., Aguilar M., Cheung R., et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology: 2015; 148 3 547 555
2. Charlton M. R., Burns J. M., Pedersen R. A., Watt K. D., Heimbach J. K., Dierkhising R. A. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology: 2011; 141 4 1249 1253
3. Pais R., Charlotte F., Fedchuk L., et al. LIDO Study Group. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol: 2013; 59 3 550 556
4. McPherson S., Hardy T., Henderson E., Burt A. D., Day C. P., Anstee Q. M. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol: 2015; 62 5 1148 1155
5. Matteoni C. A., Younossi Z. M., Gramlich T., Boparai N., Liu Y. C., McCullough A. J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology: 1999; 116 6 1413 1419
6. Teli M. R., James O. F., Burt A. D., Bennett M. K., Day C. P. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology: 1995; 22 6 1714 1719
7. Dam-Larsen S., Becker U., Franzmann M. B., Larsen K., Christoffersen P., Bendtsen F. Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol: 2009; 44 10 1236 1243
8. Ekstedt M., Hagström H., Nasr P., et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology: 2015; 61 5 1547 1554
9. Ekstedt M., Franzén L. E., Mathiesen U. L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology: 2006; 44 4 865 873
10. Angulo P., Machado M. V., Diehl A. M. Fibrosis in nonalcoholic Fatty liver disease: mechanisms and clinical implications. Semin Liver Dis: 2015; 35 2 132 145
11. Younossi Z. M., Stepanova M., Rafiq N., et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology: 2011; 53 6 1874 1882
12. Angulo P., Kleiner D. E., Dam-Larsen S., et al. Liver fibrosis, but no other histologic features is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology: 2015; 149 2 389 397 e10
13. Sanyal A. J., Brunt E. M., Kleiner D. E., et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology: 2011; 54 1 344 353
14. Chalasani N., Younossi Z., Lavine J. E., et al. American Gastroenterological Association; American Association for the Study of Liver Diseases; American College of Gastroenterologyh. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology: 2012; 142 7 1592 1609
15. Chung M. Y., Yeung S. F., Park H. J., Volek J. S., Bruno R. S. Dietary α- and γ-tocopherol supplementation attenuates lipopolysaccharide-induced oxidative stress and inflammatory-related responses in an obese mouse model of nonalcoholic steatohepatitis. J Nutr Biochem: 2010; 21 12 1200 1206
16. Hasegawa T., Yoneda M., Nakamura K., Makino I., Terano A. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther: 2001; 15 10 1667 1672
17. Sanyal A. J., Mofrad P. S., Contos M. J., et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol: 2004; 2 12 1107 1115
18. Guy C. D., Suzuki A., Abdelmalek M. F., Burchette J. L., Diehl A. M.; NASH CRN. Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity. Hepatology: 2015; 61 1 98 107
19. Harrison S. A., Torgerson S., Hayashi P., Ward J., Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol: 2003; 98 11 2485 2490
20. Kugelmas M., Hill D. B., Vivian B., Marsano L., McClain C. J. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology: 2003; 38 2 413 419
21. Yakaryilmaz F., Guliter S., Ozenirler S., Erdem O., Akyol G. Vitamin E treatment in patients with nonalcoholic steatohepatitis: A six-month, open-label study of sixteen patients. Curr Ther Res Clin Exp: 2004; 65 3 266 277
22. Dufour J. F., Oneta C. M., Gonvers J. J., et al. Swiss Association for the Study of the Liver. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol: 2006; 4 12 1537 1543
23. Sanyal A. J., Chalasani N., Kowdley K. V., et al. NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med: 2010; 362 18 1675 1685
24. Pietu F., Guillaud O., Walter T., et al. Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: long-term results. Clin Res Hepatol Gastroenterol: 2012; 36 2 146 155
25. Wang C. L., Liang L., Fu J. F., et al. Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children. World J Gastroenterol: 2008; 14 10 1598 1602
26. Lavine J. E., Schwimmer J. B., Van Natta M. L., et al. Nonalcoholic Steatohepatitis Clinical Research Network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA: 2011; 305 16 1659 1668
27. Pacana T., Sanyal A. J. Vitamin E and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care: 2012; 15 6 641 648
28. Berry D., Wathen J. K., Newell M. Bayesian model averaging in meta-analysis: vitamin E supplementation and mortality. Clin Trials: 2009; 6 1 28 41
29. Dietrich M., Jacques P. F., Pencina M. J., et al. Vitamin E supplement use and the incidence of cardiovascular disease and all-cause mortality in the Framingham Heart Study: Does the underlying health status play a role? Atherosclerosis: 2009; 205 2 549 553
30. Miller E. R. III, Pastor-Barriuso R., Dalal D., Riemersma R. A., Appel L. J., Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med: 2005; 142 1 37 46
31. Bjelakovic G., Nikolova D., Gluud L. L., Simonetti R. G., Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA: 2007; 297 8 842 857
32. Gerss J., Köpcke W. The questionable association of vitamin E supplementation and mortality-inconsistent results of different meta-analytic approaches. Cell Mol Biol (Noisy-le-grand): 2009; 55 (Suppl): OL1111 OL1120
33. Klein E. A., Thompson I. M. Jr, Tangen C. M., et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA: 2011; 306 14 1549 1556
34. Yki-Järvinen H. Thiazolidinediones. N Engl J Med: 2004; 351 11 1106 1118
35. Sharma A. M., Staels B. Review: Peroxisome proliferator-activated receptor gamma and adipose tissue-understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab: 2007; 92 2 386 395
36. Libby P., Plutzky J. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. Am J Cardiol: 2007; 99 (4A): 27B 40B
37. Lee C. H., Olson P., Evans R. M. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology: 2003; 144 6 2201 2207
38. Orasanu G., Ziouzenkova O., Devchand P. R., et al. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice. J Am Coll Cardiol: 2008; 52 10 869 881
39. Neuschwander-Tetri B. A., Brunt E. M., Wehmeier K. R., Oliver D., Bacon B. R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology: 2003; 38 4 1008 1017
40. Tiikkainen M., Häkkinen A. M., Korsheninnikova E., Nyman T., Mäkimattila S., Yki-Järvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes: 2004; 53 8 2169 2176
41. Ratziu V., Giral P., Jacqueminet S., et al. LIDO Study Group. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology: 2008; 135 1 100 110
42. Ratziu V., Charlotte F., Bernhardt C., et al. LIDO Study Group. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology: 2010; 51 2 445 453
43. Omer Z., Cetinkalp S., Akyildiz M., et al. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol: 2010; 22 1 18 23
44. Torres D. M., Jones F. J., Shaw J. C., Williams C. D., Ward J. A., Harrison S. A. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial. Hepatology: 2011; 54 5 1631 1639
45. Promrat K., Lutchman G., Uwaifo G. I., et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology: 2004; 39 1 188 196
46. Belfort R., Harrison S. A., Brown K., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med: 2006; 355 22 2297 2307
47. Aithal G. P., Thomas J. A., Kaye P. V., et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology: 2008; 135 4 1176 1184
48. Boettcher E., Csako G., Pucino F., Wesley R., Loomba R. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther: 2012; 35 1 66 75
49. Lutchman G., Modi A., Kleiner D. E., et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology: 2007; 46 2 424 429
50. Cusi K., Orsak B., Lomonaco R., et al. Extended treatment with pioglitazone improves liver histology in patients with prediabetes or type 2 diabetes mellitus and NASH. Hepatology: 2013; 58: Abstract 82
51. Azoulay L., Yin H., Filion K. B., et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ: 2012; 344 e3645
52. Bennett W. L., Maruthur N. M., Singh S., et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med: 2011; 154 9 602 613
53. Lincoff A. M., Wolski K., Nicholls S. J., Nissen S. E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA: 2007; 298 10 1180 1188
54. Flachs P., Rossmeisl M., Bryhn M., Kopecky J. Cellular and molecular effects of n-3 polyunsaturated fatty acids on adipose tissue biology and metabolism. Clin Sci (Lond): 2009; 116 1 1 16
55. Flachs P., Rossmeisl M., Kopecky J. The effect of n-3 fatty acids on glucose homeostasis and insulin sensitivity. Physiol Res: 2014; 63 01 S93 S118
56. Wu J. H., Cahill L. E., Mozaffarian D. Effect of fish oil on circulating adiponectin: a systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab: 2013; 98 6 2451 2459
57. López-Vicario C., González-Périz A., Rius B., et al. Molecular interplay between Δ5/Δ6 desaturases and long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis. Gut: 2014; 63 2 344 355
58. Capanni M., Calella F., Biagini M. R., et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther: 2006; 23 8 1143 1151
59. Spadaro L., Magliocco O., Spampinato D., et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis: 2008; 40 3 194 199
60. Tanaka N., Sano K., Horiuchi A., Tanaka E., Kiyosawa K., Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol: 2008; 42 4 413 418
61. Zhu F. S., Liu S., Chen X. M., Huang Z. G., Zhang D. W. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol: 2008; 14 41 6395 6400
62. Sofi F., Giangrandi I., Cesari F., et al. Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study. Int J Food Sci Nutr: 2010; 61 8 792 802
63. Nobili V., Alisi A., Della Corte C., et al. Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children. Nutr Metab Cardiovasc Dis: 2013; 23 11 1066 1070
64. Parker H. M., Johnson N. A., Burdon C. A., Cohn J. S., O'Connor H. T., George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol: 2012; 56 4 944 951
65. Scorletti E., Bhatia L., McCormick K. G., et al. WELCOME Study. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome∗ study. Hepatology: 2014; 60 4 1211 1221
66. Sanyal A. J., Abdelmalek M. F., Suzuki A., Cummings O. W., Chojkier M.; EPE-A Study Group. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology: 2014; 147 2 377 384.e1
67. Argo C. K., Patrie J. T., Lackner C., et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J Hepatol: 2015; 62 1 190 197
68. DeFronzo R. A., Barzilai N., Simonson D. C. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab: 1991; 73 6 1294 1301
69. Glueck C. J., Fontaine R. N., Wang P., et al. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism: 2001; 50 7 856 861
70. Pernicova I., Korbonits M. Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol: 2014; 10 3 143 156
71. Haukeland J. W., Konopski Z., Eggesbo H. B., et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol: 2009; 44 7 853 860
72. Nair S., Diehl A. M., Wiseman M., Farr G. H. Jr, Perrillo R. P. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther: 2004; 20 1 23 28
73. Shields W. W., Thompson K. E., Grice G. A., Harrison S. A., Coyle W. J. The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial. Therap Adv Gastroenterol: 2009; 2 3 157 163
74. Rakoski M. O., Singal A. G., Rogers M. A., Conjeevaram H. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther: 2010; 32 10 1211 1221
75. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., Fruchart J. C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation: 1998; 98 19 2088 2093
76. Basaranoglu M., Acbay O., Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol: 1999; 31 2 384
77. Fernández-Miranda C., Pérez-Carreras M., Colina F., López-Alonso G., Vargas C., Solís-Herruzo J. A. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis: 2008; 40 3 200 205
78. Laurin J., Lindor K. D., Crippin J. S., et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology: 1996; 23 6 1464 1467
79. Fabbrini E., Mohammed B. S., Korenblat K. M., et al. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab: 2010; 95 6 2727 2735
80. Athyros V. G., Mikhailidis D. P., Didangelos T. P., et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin: 2006; 22 5 873 883
81. Han K. H., Rha S. W., Kang H. J., et al. Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage). J Clin Lipidol: 2012; 6 4 340 351
82. Hatzitolios A., Savopoulos C., Lazaraki G., et al. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol: 2004; 23 4 131 134
83. Kiyici M., Gulten M., Gurel S., et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol: 2003; 17 12 713 718
84. Foster T., Budoff M. J., Saab S., Ahmadi N., Gordon C., Guerci A. D. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol: 2011; 106 1 71 77
85. Ekstedt M., Franzén L. E., Mathiesen U. L., Holmqvist M., Bodemar G., Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol: 2007; 47 1 135 141
86. Hyogo H., Tazuma S., Arihiro K., et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism: 2008; 57 12 1711 1718
87. Nelson A., Torres D. M., Morgan A. E., Fincke C., Harrison S. A. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol: 2009; 43 10 990 994
88. Athyros V. G., Tziomalos K., Gossios T. D., et al. GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet: 2010; 376 9756 1916 1922
89. Chalasani N., Aljadhey H., Kesterson J., Murray M. D., Hall S. D. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology: 2004; 126 5 1287 1292
90. Lewis J. H., Mortensen M. E., Zweig S., Fusco M. J., Medoff J. R., Belder R.; Pravastatin in Chronic Liver Disease Study Investigators. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology: 2007; 46 5 1453 1463
91. Oakley F., Teoh V., Ching-A-Sue G., et al. Angiotensin II activates I kappaB kinase phosphorylation of RelA at Ser 536 to promote myofibroblast survival and liver fibrosis. Gastroenterology: 2009; 136 7 2334 2344.e1
92. Moreno M., Gonzalo T., Kok R. J., et al. Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology: 2010; 51 3 942 952
93. Moreira de Macêdo S., Guimarães T. A., Feltenberger J. D., Sousa Santos S. H. The role of renin-angiotensin system modulation on treatment and prevention of liver diseases. Peptides: 2014; 62 189 196
94. Goh G. B., Pagadala M. R., Dasarathy J., et al. Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease. Liver Int: 2015; 35 3 979 985
95. Fogari R., Maffioli P., Mugellini A., Zoppi A., Lazzari P., Derosa G. Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. Eur J Gastroenterol Hepatol: 2012; 24 2 164 171
96. Georgescu E. F., Ionescu R., Niculescu M., Mogoanta L., Vancica L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol: 2009; 15 8 942 954
97. Koppe S. W., Sahai A., Malladi P., Whitington P. F., Green R. M. Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. J Hepatol: 2004; 41 4 592 598
98. Strieter R. M., Remick D. G., Ward P. A., et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun: 1988; 155 3 1230 1236
99. Zein C. O., Lopez R., Fu X., et al. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology: 2012; 56 4 1291 1299
100. Satapathy S. K., Garg S., Chauhan R., et al. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol: 2004; 99 10 1946 1952
101. Adams L. A., Zein C. O., Angulo P., Lindor K. D. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol: 2004; 99 12 2365 2368
102. Zein C. O., Yerian L. M., Gogate P., et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology: 2011; 54 5 1610 1619
103. Van Wagner L. B., Koppe S. W., Brunt E. M., et al. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol: 2011; 10 3 277 286
104. Lazaridis K. N., Gores G. J., Lindor K. D. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders' J Hepatol: 2001; 35 1 134 146
105. Ratziu V., de Ledinghen V., Oberti F., et al. FRESGUN. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol: 2011; 54 5 1011 1019
106. Leuschner U. F., Lindenthal B., Herrmann G., et al. NASH Study Group. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology: 2010; 52 2 472 479
107. Lindor K. D., Kowdley K. V., Heathcote E. J., et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology: 2004; 39 3 770 778
108. Adorini L., Pruzanski M., Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today: 2012; 17 17-18 988 997
109. Mazuy C., Helleboid A., Staels B., Lefebvre P. Nuclear bile acid signaling through the farnesoid X receptor. Cell Mol Life Sci: 2015; 72 9 1631 1650
110. Mudaliar S., Henry R. R., Sanyal A. J., et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology: 2013; 145 3 574 582.e1
111. Neuschwander-Tetri B. A., Loomba R., Sanyal A. J., et al. NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet: 2015; 385 9972 956 965
112. Kharitonenkov A., Shanafelt A. B. FGF21: a novel prospect for the treatment of metabolic diseases. Curr Opin Investig Drugs: 2009; 10 4 359 364
113. Kharitonenkov A., Shiyanova T. L., Koester A., et al. FGF-21 as a novel metabolic regulator. J Clin Invest: 2005; 115 6 1627 1635
114. Coskun T., Bina H. A., Schneider M. A., et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology: 2008; 149 12 6018 6027
115. Xu J., Lloyd D. J., Hale C., et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes: 2009; 58 1 250 259
116. Fisher F. M., Chui P. C., Nasser I. A., et al. Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. Gastroenterology: 2014; 147 5 1073 83.e6
117. Gawrieh S., Alloosh M., Sheridan R., et al. Fibroblast growth factor 21 treatment improves atherogenic diet-induced liver injury and metabolic syndrome in Ossabaw miniature swine. Hepatology: 2014; 60 247A 249A
118. Kolterman O. G., Buse J. B., Fineman M. S., et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab: 2003; 88 7 3082 3089
119. Sathyanarayana P., Jogi M., Muthupillai R., Krishnamurthy R., Samson S. L., Bajaj M. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. Obesity (Silver Spring): 2011; 19 12 2310 2315
120. Samson S. L., Sathyanarayana P., Jogi M., et al. Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. Diabetologia: 2011; 54 12 3093 3100
121. Li Y., Wong K., Giles A., et al. Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21. Gastroenterology: 2014; 146 2 539 549.e7
122. Sharma S., Mells J. E., Fu P. P., Saxena N. K., Anania F. A. GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS ONE: 2011; 6 9 e25269
123. Kenny P. R., Brady D. E., Torres D. M., Ragozzino L., Chalasani N., Harrison S. A. Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series. Am J Gastroenterol: 2010; 105 12 2707 2709
124. Eguchi Y., Kitajima Y., Hyogo H., et al. Japan Study Group for NAFLD (JSG-NAFLD). Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol Res: 2015; 45 3 269 278
125. Armstrong M. JGP, Aithal G. P., Parker R., et al. Liraglutide is effective in the histological clearance of nonalcoholic steatohepatitis in a multicenter, double-blinded, randomized, placebo-controlled phase II trial. J Hepatol: 2015; 62 S271
126. Prescott L. F., Newton R. W., Swainson C. P., Wright N., Forrest A. R., Matthew H. Successful treatment of severe paracetamol overdosage with cysteamine. Lancet: 1974; 1 7858 588 592
127. Prescott L. F., Sutherland G. R., Park J., Smith I. J., Proudfoot A. T. Cysteamine, methionine, and penicillamine in the treatment of paracetamol poisoning. Lancet: 1976; 2 7977 109 113
128. Dohil R., Schmeltzer S., Cabrera B. L., et al. Enteric-coated cysteamine for the treatment of paediatric non-alcoholic fatty liver disease. Aliment Pharmacol Ther: 2011; 33 9 1036 1044
129. Van Bergen T., Marshall D., Van de Veire S., et al. The role of LOX and LOXL2 in scar formation after glaucoma surgery. Invest Ophthalmol Vis Sci: 2013; 54 8 5788 5796
130. Traber P. G., Zomer E. Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS ONE: 2013; 8 12 e83481
131. Traber P. G., Chou H., Zomer E., et al. Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PLoS ONE: 2013; 8 10 e75361
132. Harrison S., Chalasani N., Lawitz E., et al. Early phase 1 clinical trial results of GR-MD-02, a galec-tin-3 inhibitor, in patients having non-alcoholic steato-hepatitis (NASH) with advanced fibrosis. Hepatology: 2014; 60 224A 227A
133. Lefebvre E., Hashiguchi T., Jenkins H., et al. Anti-fibrotic and anti-inflammatory activity of the dual CCR2 and CCR5 antagonist cenicriviroc in a mouse model of NASH. Hepatology: 2013; 58 219A 222A
134. Gilat T., Leikin-Frenkel A., Goldiner I., et al. Prevention of diet-induced fatty liver in experimental animals by the oral administration of a fatty acid bile acid conjugate (FABAC). Hepatology: 2003; 38 2 436 442
135. Leikin-Frenkel A., Goldiner I., Leikin-Gobbi D., et al. Treatment of preestablished diet-induced fatty liver by oral fatty acid-bile acid conjugates in rodents. Eur J Gastroenterol Hepatol: 2008; 20 12 1205 1213
136. Safadi R., Konikoff F. M., Mahamid M., et al. FLORA Group. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol: 2014; 12 12 2085 2091.e1
137. Cariou B., Staels B. GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes. Expert Opin Investig Drugs: 2014; 23 10 1441 1448
138. Quintero P., Arrese M. Nuclear control of inflammation and fibrosis in nonalcoholic steatohepatitis: therapeutic potential of dual peroxisome proliferator-activated receptor alpha/delta agonism. Hepatology: 2013; 58 6 1881 1884
139. Staels B., Rubenstrunk A., Noel B., et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology: 2013; 58 6 1941 1952
140. Genfit Press Release: New Proof of Efficacy of GFT505 in NASH and Positive Expert Opinion. Available at: http://www.genfit.com/wp-content/uploads/2015/04/2015.04.24-PR-GENFIT-EASL-Minutes.pdf. Accessed May 23, 2015